Estrella Immunopharma (ESLA) Free Cash Flow (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Free Cash Flow of -$6.7 million for Q1 2026, down 1337.83% year-over-year from $541271.2 in Q1 2025, and down 3393.08% quarter-over-quarter from -$191808.0 in Q4 2025.
Estrella Immunopharma (ESLA) Free Cash Flow (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Free Cash Flow for 6 consecutive years, with -$6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 1337.83% year-over-year to -$6.7 million; the TTM figure through Mar 2026 stood at -$8.0 million (up 45.9% YoY), while the FY2025 annual figure was -$1.8 million, up 76.44% from the prior year.
- Free Cash Flow fell to -$6.7 million in Q1 2026 per ESLA's latest filing, from -$191808.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at -$157144.0 in Q1 2022 and bottomed at -$6.7 million in Q3 2024.
- Historically, Free Cash Flow has averaged -$2.2 million across 5 years, with a median of -$1.1 million in 2022.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 19087.3% — and 2025, when it soared 93.84%.
- Estrella Immunopharma's Free Cash Flow stood at -$1.2 million in 2022, then tumbled by 297.09% to -$4.8 million in 2023, then surged by 35.12% to -$3.1 million in 2024, then jumped by 93.84% to -$191808.0 in 2025, then sank by 3393.08% to -$6.7 million in 2026.
- Business Quant data shows ESLA's Free Cash Flow at -$6.7 million in Q1 2026, -$191808.0 in Q4 2025, and -$727332.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.80 Mn |
| Jun 30, 2026 | -1.80 Mn |
| Mar 31, 2026 | -6.70 Mn |
| Mar 31, 2026 | -6.70 Mn |
| Dec 31, 2025 | -191,808.00 |
| Dec 31, 2025 | -191,808.00 |
| Sep 30, 2025 | -727,332.00 |
| Sep 30, 2025 | -727,332.00 |
| Jun 30, 2025 | -414,879.00 |
| Jun 30, 2025 | -414,879.00 |
| Mar 31, 2025 | -465,981.00 |
| Mar 31, 2025 | -465,981.00 |
| Dec 31, 2024 | -3.11 Mn |
| Dec 31, 2024 | -3.11 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Sep 30, 2024 | -6.74 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.23 Mn |
| Mar 31, 2024 | -4.23 Mn |